Compare ELME & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | CRBP |
|---|---|---|
| Founded | 1960 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.9M | 184.4M |
| IPO Year | 1994 | 2014 |
| Metric | ELME | CRBP |
|---|---|---|
| Price | $1.49 | $9.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $12.67 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 1.9M | 486.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 707.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | $4,822,272.00 |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.31 | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.26 | $7.12 |
| 52 Week High | $17.68 | $20.56 |
| Indicator | ELME | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 24.64 | 58.41 |
| Support Level | N/A | $7.42 |
| Resistance Level | $2.22 | $9.57 |
| Average True Range (ATR) | 0.05 | 0.49 |
| MACD | -0.06 | 0.22 |
| Stochastic Oscillator | 28.75 | 96.72 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.